A study of treatment for medulloblastoma using sodium thiosulfate to prevent hearing loss
Full IRB Study Title:
ACNS2031: A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features
IRB Study ID: 2022-210
For complete details, please view the study on clinicaltrials.gov
Study Sponsor:
Children's Oncology Group
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Erin Wright, MD
Director, Neuro-Oncology; Director, Shannon E. Wilkes Targeted Therapy Program; Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Co-Director, Neurofibromatosis Clinic; Pediatric Neuro-Oncologist
Pediatric Brain Tumor ProgramShowers Family Center for Childhood Cancer and Blood DisordersNeurofibromatosis (NF) Clinic
